Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene
International Journal of Developmental Neuroscience · 2025
DOI: 10.1002/jdn.70049 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Developmental Neuroscience, 2025. Verfasst von Song Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Mutation, Neurofibromin 1, Benzimidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Neurofibromatosis type 1 ( NF1 ) is an autosomal dominant genetic disorder, with plexiform neurofibromas occurring in approximately 20%–50% of patients. A 12‐year‐old girl underwent surgery due to unbearable pain caused by diffuse neurofibromas. Postoperatively, the girl exhibited rapid growth and extremely extensive plexiform neurofibromas, with multiple plexiform neurofibromas that were inoperable. Through high‐throughput sequencing (HTS), genetic molecular analysis was conducted on the peripheral blood samples of the child, and it was found that there was a splice site mutation c.3113 + 1G > A in the NF1 gene. Additionally, we identified a pathogenic variant c.2033dup (Ile679Aspfs*21), citing ClinVar and PMID: 77655472 to confirm its established pathogenicity in the paraffin‐embedded section sample of the diffuse neurofibroma, which was exclusively found in the girl's plexiform neurofibroma. This ‘second‐hit’ mutation could explain the rapid growth of the diffuse neurofibroma. The patient was effectively treated with oral administration of the selective MEK inhibitor selumetinib, resulting in rapid tumour regression. The treatment has shown promising efficacy against the rapid tumour growth induced by the patient's ‘second‐hit’ mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
- Department of Neurology, Jinan Children's Hospital, Jinan, Shandong, China.
- Department of Pathology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
- Department of Pathology, Jinan Children's Hospital, Jinan, Shandong, China.
- Department of Medical Imaging, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
- Department of Medical Imaging, Jinan Children's Hospital, Jinan, Shandong, China.
Zitieren
APA
Su, S., Bai, Y., Lu, Y., Ren, Y., Zhang, W., Wang, G., Ma, K., & Zhang, H. (2025). Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene. International Journal of Developmental Neuroscience. https://doi.org/10.1002/jdn.70049
Vancouver
Su S, Bai Y, Lu Y, Ren Y, Zhang W, Wang G, et al. Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene. International Journal of Developmental Neuroscience. 2025. doi:10.1002/jdn.70049
BibTeX
@article{Su2025,
author = {Su, Song and Bai, Yuexia and Lu, Yi and Ren, Ying and Zhang, Wenchao and Wang, Guangyu and Ma, Kai and Zhang, Hongwei},
title = {Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene},
journal = {International Journal of Developmental Neuroscience},
year = {2025},
doi = {10.1002/jdn.70049}
}
EUVIMED